Clostridium Botulinum, Neurotoxin Serotype A/B

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

10 Countries

Phase II

Phase I (FiH)

Phase II: 2 Phase I (FiH): 2

Sponsors using this IMP

Ipsen Innovation 4

All trials

4 total

A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting

2024-519248-34-00 Phase II 6 countries Ipsen Innovation
A study to assess the safety and efficacy of IPN10200 in adult participants with moderate to severe upper facial lines Recruiting

2024-512782-14-00 Phase I (FiH) 2 countries Ipsen Innovation
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Phase I (FiH) 10 countries Ipsen Innovation
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Ended

2024-511101-28-00 Phase II 5 countries Ipsen Innovation

Showing 1–4 of 4 trials

← All drugs A–Z